Cargando…
Validation of the 30-Year Framingham Risk Score in a German Population-Based Cohort
The Framingham Risk Score to predict 30-year risk (FRS30y) of cardiovascular disease (CVD) constitutes an important tool for long-term risk prediction. However, due to its complex statistical properties and the paucity of large population-based cohorts with appropriate data, validation of the FRS30y...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025787/ https://www.ncbi.nlm.nih.gov/pubmed/35454012 http://dx.doi.org/10.3390/diagnostics12040965 |
_version_ | 1784690960496590848 |
---|---|
author | Rospleszcz, Susanne Starnecker, Fabian Linkohr, Birgit von Scheidt, Moritz Gieger, Christian Schunkert, Heribert Peters, Annette |
author_facet | Rospleszcz, Susanne Starnecker, Fabian Linkohr, Birgit von Scheidt, Moritz Gieger, Christian Schunkert, Heribert Peters, Annette |
author_sort | Rospleszcz, Susanne |
collection | PubMed |
description | The Framingham Risk Score to predict 30-year risk (FRS30y) of cardiovascular disease (CVD) constitutes an important tool for long-term risk prediction. However, due to its complex statistical properties and the paucity of large population-based cohorts with appropriate data, validation of the FRS30y is lacking. A population-based cohort from Southern Germany (N = 3110, 1516 (48.7%) women) was followed up for a median time of 29.5 [18.7, 31.2] years. Discrimination and calibration were assessed for the original, recalibrated and refitted FRS30y version. During follow up, 620 incident CVD events (214 in women) occurred. The FRS30y showed adequate discrimination (original and recalibrated version: Area under the curve (AUC): 78.4 for women and 74.9 for men) but overestimated actual CVD risk (original version: discordance 45.4% for women and 37.3% for men, recalibrated version: 37.6% and 28.6%, respectively). Refitting showed substantial improvement in neither discrimination nor calibration. The performance of FRS30y is adequate for long-term CVD risk prediction and could serve as an important tool in risk communication, especially for younger audiences. |
format | Online Article Text |
id | pubmed-9025787 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90257872022-04-23 Validation of the 30-Year Framingham Risk Score in a German Population-Based Cohort Rospleszcz, Susanne Starnecker, Fabian Linkohr, Birgit von Scheidt, Moritz Gieger, Christian Schunkert, Heribert Peters, Annette Diagnostics (Basel) Article The Framingham Risk Score to predict 30-year risk (FRS30y) of cardiovascular disease (CVD) constitutes an important tool for long-term risk prediction. However, due to its complex statistical properties and the paucity of large population-based cohorts with appropriate data, validation of the FRS30y is lacking. A population-based cohort from Southern Germany (N = 3110, 1516 (48.7%) women) was followed up for a median time of 29.5 [18.7, 31.2] years. Discrimination and calibration were assessed for the original, recalibrated and refitted FRS30y version. During follow up, 620 incident CVD events (214 in women) occurred. The FRS30y showed adequate discrimination (original and recalibrated version: Area under the curve (AUC): 78.4 for women and 74.9 for men) but overestimated actual CVD risk (original version: discordance 45.4% for women and 37.3% for men, recalibrated version: 37.6% and 28.6%, respectively). Refitting showed substantial improvement in neither discrimination nor calibration. The performance of FRS30y is adequate for long-term CVD risk prediction and could serve as an important tool in risk communication, especially for younger audiences. MDPI 2022-04-12 /pmc/articles/PMC9025787/ /pubmed/35454012 http://dx.doi.org/10.3390/diagnostics12040965 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rospleszcz, Susanne Starnecker, Fabian Linkohr, Birgit von Scheidt, Moritz Gieger, Christian Schunkert, Heribert Peters, Annette Validation of the 30-Year Framingham Risk Score in a German Population-Based Cohort |
title | Validation of the 30-Year Framingham Risk Score in a German Population-Based Cohort |
title_full | Validation of the 30-Year Framingham Risk Score in a German Population-Based Cohort |
title_fullStr | Validation of the 30-Year Framingham Risk Score in a German Population-Based Cohort |
title_full_unstemmed | Validation of the 30-Year Framingham Risk Score in a German Population-Based Cohort |
title_short | Validation of the 30-Year Framingham Risk Score in a German Population-Based Cohort |
title_sort | validation of the 30-year framingham risk score in a german population-based cohort |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025787/ https://www.ncbi.nlm.nih.gov/pubmed/35454012 http://dx.doi.org/10.3390/diagnostics12040965 |
work_keys_str_mv | AT rospleszczsusanne validationofthe30yearframinghamriskscoreinagermanpopulationbasedcohort AT starneckerfabian validationofthe30yearframinghamriskscoreinagermanpopulationbasedcohort AT linkohrbirgit validationofthe30yearframinghamriskscoreinagermanpopulationbasedcohort AT vonscheidtmoritz validationofthe30yearframinghamriskscoreinagermanpopulationbasedcohort AT giegerchristian validationofthe30yearframinghamriskscoreinagermanpopulationbasedcohort AT schunkertheribert validationofthe30yearframinghamriskscoreinagermanpopulationbasedcohort AT petersannette validationofthe30yearframinghamriskscoreinagermanpopulationbasedcohort |